Publications

Books and Chapters

  • Abdul-Mutakabbir JC, Tan K. COVID-19 and Secondary Bacterial Infections; With A Focus on The Importance of Antimicrobial Stewardship. COVID-19 VIRAL SEPSIS: Early recognition, management and prevention Impact on Health Disparities, Disability and Death. Elsevier. (submitted)  (01/2022)
  • Allen J, Abdul-Mutakabbir JC. Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics. Lippincott Illustrated Reviews: Pharmacology, Eighth Edition. (Revisions Submitted) (01/2022)

Scholarly Journals--Accepted

  • FakhriRavari A, Simiyu B, Morrisette T, Dayo Y, Abdul-Mutakabbir JC (Senior Author) How to manage Gram-positive and Gram-negative Pathogen Conundrums with Dual Beta-lactam therapy. Drugs in Context. (12/2021)
  • Abdul-Mutakabbir JC, Arya V, Butler L. Acknowledging the Intersection of Gender Inequity and Racism: Identifying a Path Forward in Pharmacy. American Journal of Health-System Pharmacy. (12/2021)

Scholarly Journals--Published

  • Dubov A, Distelberg B, Abdul-Mutakabbir JC…Chrissian, A. Predictors of COVID-19 vaccine acceptance and hesitancy among healthcare workers in Southern California: not just ‘anti’ vs ‘pro-vaccine”. Vaccines. (12/2021)
  • Campbell H, Abdul-Mutakabbir JC, Hodge D. The (Contrasted) Ethics of Covid-19 and HIV: Will the favor be returned?. Journal of Healthcare, Science and The Humanities. (12/2021)
  • Abdul-Mutakabbir JC (Corresponding Author), Griffith N, Shields RK, Tverdk F, Escobar, Z. SIDP Insights: Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections. Infectious Diseases and Therapy. (10/2021)
  • Kebriaei R, Stamper K, Lev K, Morrisette T, Abdul-Mutakabbir J, Schuch R, Lehoux D. Rybak MJ. Exebacase, in Addition to Daptomycin against MRSA. Antimicrobial Agents and Chemotherapy. (08/2021)
  • Marcelin J, Swartz T, Fidelia B,…Abdul-Mutakabbir JC (Senior Author) Addressing and Inspiring Vaccine Confidence in Black, Indigenous, and People of Color (BIPOC) during the COVID-19 Pandemic. Open Forum Infectious Diseases. Open Forum Infectious Diseases. (08/2021)
  • Marcelin JR, Fadul N, Cawcutt KA, Abdul-Mutakabbir JC. Diversity in Probiotics and diversity in clinical trials: Opportunities for Improvement. Infection Control and Hospital Epidemiology. (07/2021)
  • Abdul-Mutakabbir JC, Nguyen L, Kebriaei R, Stamper K, Maassen P, Lev K, Kaye K, Rybak MJ. In-Vitro Antibacterial Activities of Cefiderocol (S-649266) against Multidrug-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. (06/2021)
  • Abdul-Mutakabbir JC, Kebriaei R, Stamper K, Maassen P, Lev K, Rybak MJ. Dalbavancin, Vancomycin, and Daptomycin alone and in Combination with Cefazolin against resistant phenotypes of Staphylococcus aureus. Antibiotics. Sept 2020. (04/2021)
  • Peteet B, Belliard JC, Abdul-Mutakabbir J, Casey S, Simmons K. Community-Academic Partnerships to Reduce COVID-19 Vaccine Hesitancy in Minoritized Communities. EClinicalMedicine (Published by THE LANCET). March 2021. (03/2021)
  • Abdul-Mutakabbir JC, Casey S, Jews V, King A, Simmons K, Hogue M, Belliard JC, Peverini R, Veltman J. A Three-Tiered Approach to Address Barriers in COVID-19 Vaccine Delivery Within the Black Community. The Lancet Global Health. March 2021. (03/2021)
  • Allen J, Abdul-Mutakabbir JC, Campbell H, Butler L. Ten Recommendations to Increase Black Representation within Pharmacy Organization Leadership. American Journal of Health-System Pharmacy. Feb 2021. (02/2021)
  • Morrisette T, Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Rybak MJ. The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics. (10/2020)
  • Abdul-Mutakabbir JC, Kebriaei R, Stamper K, Maassen P, Lev K, Rybak MJ. Dalbavancin, Vancomycin, and Daptomycin alone and in Combination with Cefazolin against resistant phenotypes of Staphylococcus aureus. Antibiotics. Sept 2020. (10/2020)
  • Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ. Cefiderocol: A Novel Siderophore Cephalosporin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Oct 2020. (10/2020)
  • Kebriaei R, Lev K, Morrisette T, Stamper K, Abdul-Mutakabbir JC, Morales S, Rybak MJ. Bacteriophage-Antibiotic Combination Strategy: An Alternative against Methicillin-resistant Phenotypes of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. (05/2020)
  • Alosaimy S, Abdul-Mutakabbir JC, Jorgensen SCJ, Kebriaei R, Rybak MJ. Eravacycline Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. (01/2020)
  • Jorgensen SCJ, Zasowski E, Trang T, Lagnf A, Bhatia S, Sabagha N, Abdul-Mutakabbir JC, Alosaimy S, Mynatt R, Davis S, Rybak MJ. Daptomycin plus beta-lactam for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis. (06/2019)
  • Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin. (03/2019)

Scholarly Journals--Submitted

  • Peteet B, Watts V….Abdul-Mutakabbir JC, Casey S, Simmons K. Faith, Fear, and Facts; A COVID-19 Vaccination Hesitancy intervention for Black Churchgoers. Journal of Racial and Ethnic Health Disparities. (07/2021)

Abstract

  • Morrisette TM, Kebriaei R, Lev K, Abdul-Mutakabbir JC, Rybak MJ. Bacteriophage-antibiotic Combinations for Enterococcus faecium with varying Daptomycin and Bacteriophage Susceptibilities. Antimicrobial Agents and Chemotherapy. (05/2020)